Accuray Incorporated (ARAY) Shares Bought by Royce & Associates LP
Royce & Associates LP lifted its stake in shares of Accuray Incorporated (NASDAQ:ARAY) by 6.9% during the 2nd quarter, Holdings Channel reports. The firm owned 2,099,812 shares of the medical equipment provider’s stock after buying an additional 135,785 shares during the quarter. Royce & Associates LP’s holdings in Accuray were worth $8,609,000 as of its most recent SEC filing.
Other hedge funds also recently modified their holdings of the company. Sei Investments Co. bought a new position in shares of Accuray during the first quarter worth about $107,000. First Trust Advisors LP lifted its position in shares of Accuray by 113.1% during the second quarter. First Trust Advisors LP now owns 27,337 shares of the medical equipment provider’s stock worth $112,000 after purchasing an additional 14,508 shares during the last quarter. KBC Group NV bought a new position in shares of Accuray during the second quarter worth about $112,000. Element Capital Management LLC bought a new position in shares of Accuray during the first quarter worth about $141,000. Finally, Redmile Group LLC bought a new position in shares of Accuray during the first quarter worth about $145,000. 84.36% of the stock is currently owned by institutional investors and hedge funds.
Several brokerages have recently commented on ARAY. BTIG Research reaffirmed a “hold” rating on shares of Accuray in a research report on Wednesday, August 22nd. Jefferies Financial Group reissued a “buy” rating and issued a $6.00 target price on shares of Accuray in a report on Friday, August 17th. Citigroup cut their target price on shares of Accuray from $4.00 to $3.50 and set a “sell” rating on the stock in a report on Friday, August 17th. BidaskClub cut shares of Accuray from a “sell” rating to a “strong sell” rating in a report on Friday, August 17th. Finally, Zacks Investment Research raised shares of Accuray from a “strong sell” rating to a “hold” rating in a report on Tuesday, July 3rd. Three equities research analysts have rated the stock with a sell rating, four have given a hold rating and three have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average price target of $6.68.
Accuray (NASDAQ:ARAY) last issued its earnings results on Thursday, August 16th. The medical equipment provider reported ($0.01) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.02) by $0.01. Accuray had a negative net margin of 5.90% and a negative return on equity of 43.31%. The firm had revenue of $113.79 million for the quarter, compared to analysts’ expectations of $108.45 million. During the same quarter last year, the company posted ($0.04) earnings per share. analysts anticipate that Accuray Incorporated will post -0.1 EPS for the current fiscal year.
In other Accuray news, CFO Kevin Waters sold 14,265 shares of the firm’s stock in a transaction dated Tuesday, July 3rd. The shares were sold at an average price of $4.08, for a total value of $58,201.20. Following the transaction, the chief financial officer now owns 313,995 shares of the company’s stock, valued at $1,281,099.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Joshua Levine sold 34,235 shares of the firm’s stock in a transaction dated Tuesday, July 3rd. The stock was sold at an average price of $4.08, for a total transaction of $139,678.80. Following the completion of the transaction, the chief executive officer now directly owns 1,392,518 shares in the company, valued at approximately $5,681,473.44. The disclosure for this sale can be found here. Insiders sold 57,059 shares of company stock worth $232,801 in the last three months. 3.90% of the stock is currently owned by corporate insiders.
Accuray Company Profile
Accuray Incorporated designs, develops, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the body. The company offers the CyberKnife System, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of various types of cancer and tumors in the body.
Featured Story: Diversification in Investing
Want to see what other hedge funds are holding ARAY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Accuray Incorporated (NASDAQ:ARAY).
Receive News & Ratings for Accuray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accuray and related companies with MarketBeat.com's FREE daily email newsletter.